Go to main content
G r e a t   C h a l l e n g e .
The world’s first vaccine for hemorrhagic fever with renal syndrome The world’s second vaccine for varicella The world’s third vaccine for hepatitis-B The world’s fourth quadrivalent vaccine for flu Great Challenge toward the world, GC Biopharma Learn More >>

There are two opposing attitudes
to paths that have not been taken
Fear that there are no known paths
and excitement that new paths can be pioneered

At GC Biopharma, the fundamental question that guides our endeavors is how quickly we can develop the new drugs patients have long awaited. We have been a trailblazer in bio-pharmaceuticals, developing groundbreaking plasma derivatives, vaccines, and recombinants one after another. GC Biopharma’s dedication to innovation has brought the company shoulder to shoulder with other world-class providers of life science solutions.

A global research center leading biotechnology R&D

RED Division is to discover early drug candidates and conduct early process research and non-clinical development to confirm efficacy and toxicity whereas MSAT Division is to conduct late process research. By splitting the R&D laboratory into these two divisions, GC Biopharma desires to create effective R&D synergy effect to take a leap as a global pharmaceutical company. RED Division established a bridgehead for global new drug development by adding business development work to license in and carry out joint research for diverse novel drug candidates, to new biomedicine R&D projects based on life science technologies and innovative novel drug candidate development projects. MSAT Division is in charge of late process development for substances for which early process development has been completed. The Division is contributing to accelerating new drug development by improving the speed and efficiency of new drug development.

Localizing expensive imported treatments for hepatitis-B, hemophilia, and Other diseases

Since the establishment of a central research laboratory in 1982, GC Biopharma has led the biologics market including recombinant proteins. As a result, it succeeded in developing a novel influenza vaccine, a seasonal flu vaccine, third-generation gene recombination therapy for hemophilia, and the world’s second-ever treatment for Hunter syndrome with its own technologies. In addition, it developed IV-Globulin (IVIG), Albumin, Hepabig, Antithrombin-III, Greenplast, etc., many of which have grown as main revenue sources of the company. In order to expand and systematize the existing R&D activities, the R&D laboratory was divided into RED Division and MSAT Division to give impetus to new drug development.

The largest R&D facility in the Korean pharmaceutical industry completed in 2013

The new GC Biopharma R&D Center, established in 2013 as the largest pharmaceutical R&D facility in Korea, consists of two floors underground and five above, and sprawls over a total floor area of 28,510 m². It features facilities dedicated to new drug development, testing manufacturing processes and producing non-clinical testing agents, a cutting-edge animal testing lab, and specialized analysis facilities. By completely separating the research and office areas, the center maximizes efficiency in R&D activities. Thanks to the state-of-the-art research facilities and equipment, the center has quickly positioned itself as the forward base and chief engine for GC Biopharma’s R&D innovations.

G r e a t   C o m m i t m e n t .
A treatment for rare Hunter syndrome (only 2,000 patients nationwide) A specialized flu vaccine for seniors aged 65+ A treatment for hemophilia, a rare disease that afflicts one in 10,000 Great Commitment for humanity, GC Biopharma Learn More >>

Drugs that are difficult to make
but that must be made

Paths that are best avoided
but that must be pioneered

GC Biopharma has spearheaded the development of drugs that are extremely difficult to make, but that must be made to free patients from the despair of disease. At GC Biopharma, we have dared, with a pioneering spirit, to take on the challenge of developing specialized drugs avoided by other pharmaceutical companies. Belief in the value of a society where everyone has a chance at happiness, free from the pain of disease, leads us along this path.

A treatment for rare hunter syndrome
(only 2,000 patients nationwide)

Hunterase, the second-ever treatment in the world to be developed for hunter syndrome, was approved by the Korean ministry of food and drug safety in 2012, and epitomizes GC Biopharma’s advanced bio-pharmaceutical technology. The company is now preparing to take this innovative drug to the global market. Before GC Biopharma’s success in this area, there was only one pharmaceutical manufacturer producing a treatment for hunter syndrome. Any stoppage or shortages of supply could have grave consequences for patients. GC Biopharma aspires to increase the global market share of Hunterase to over 50 percent to change the paradigm on treating hunter syndrome. The company also intends to invest steadily in developing treatments for other rare diseases, including Fabry disease, to help improve treatment prospects and quality of life for sufferers in Korea and abroad.

A treatment for a rare disease that afflicts only one in 10,000

Greengene F is a third-generation recombinant protein treatment for hemophilia A, and the third such treatment in the world to have been developed. Epitomizing GC Biopharma’s unsurpassed technology and expertise, Phase 3 clinical trial has been completed in China, and the permission for Chinese items has been submitted, and the permission review is currently under way. The company expects the drug to generate immense added value to the Chinese pharmaceutical market, where there is great potential for growth. The company also plans to develop a new-generation and longer-acting hemophilia treatment for developed markets in North America and Europe. New Drug Application (NDA) submitted in China.

A specialized flu vaccine for seniors aged 65+

GC Biopharma has set out to research and develop a higher-dosage flu vaccine specifically for seniors. People aged 65 or older tend to show a lower immune response to flu vaccines than younger people. Whereas standard flu vaccines induce immune responses in 70 to 90 percent of healthy adults under the age of 65, this is true for only 17 to 53 percent of seniors. Developing a more effective flu vaccine for this age group is expected to reduce the societal cost of influenza epidemics.

G r e a t   C o m p a n y .
A producer of a varicella vaccine that is popular worldwide A seasonal flu vaccine that is revolutionizing the Korean and international markets An innovative recombinant protein drug for hemophilia And the world’s first verified immune cell treatment for liver cancer Great Company globally known, GC Biopharma Learn More >>

Over the last 50 years
To the next 50 years
For the 100 years of humanity
The way of a hundred-year enterprise

Our commitment to preparing for the next 50 years, High 5, GC, is a mid- to long-term 2030 plan that represents five new global medicines, 5 trillion won in sales, and 50 trillion won in corporate value. It's a strategy to become a great company that will lead the global health industry. The GC, a company which has written a new history of Korean pharmaceutical industry, is now dreaming of a vision of the next 50 years beyond the last 50 years with its mission and desire for human health.

The great enterprise spirit of the GC Biopharma

As we have walked in the last half century, we will contribute to the treatment of diseases and the health of the people through the development of difficult but essential medicines for patients. We will also implement the GC's vision to maximize the effectiveness and value of existing products, and to strengthen the new medicine pipeline for various diseases to provide a healthy life for mankind.



GC녹십자는 이메일 수집을 거부합니다

본 웹사이트에 게시된 이메일 주소가 전자우편 수집 프로그램이나
그 밖의 기술적 장치를 이용하여 무단으로 이메일 주소를 수집하는 행위를 거부하며,
이를 위반시 정보통신망 이용촉진 및 정보보호 등에 관한 법률에 의해 형사처벌됨을
유념하시기 바랍니다

게시일: 2003년 9월 1일